Current perspective on the cardiovascular effects of coxibs

Marvin A. Konstam, MD
Tufts University School of Medicine and the New England Medical Center, Boston

Matthew R. Weir, MD
University of Maryland School of Medicine, Baltimore

Correspondence: Marvin A. Konstam, MD, New England Medical Center, 750 Washington Street, Box 108, Boston, MA 02111; e-mail: mkonstam@lifespan.org

Dr. Konstam has indicated that he has been a consultant for Merck, Pfizer, and Pharmacia and is on the speakers’ bureaus of Merck and Pfizer.

Dr. Weir has indicated that he has received grant or research support from Pharmacia, has been a consultant for Merck and Pharmacia, and is on the speaker’s bureau of Merck.

Marvin A. Konstam, MD
Tufts University School of Medicine and the New England Medical Center, Boston

Matthew R. Weir, MD
University of Maryland School of Medicine, Baltimore

Correspondence: Marvin A. Konstam, MD, New England Medical Center, 750 Washington Street, Box 108, Boston, MA 02111; e-mail: mkonstam@lifespan.org

Dr. Konstam has indicated that he has been a consultant for Merck, Pfizer, and Pharmacia and is on the speakers’ bureaus of Merck and Pfizer.

Dr. Weir has indicated that he has received grant or research support from Pharmacia, has been a consultant for Merck and Pharmacia, and is on the speaker’s bureau of Merck.

Marvin A. Konstam, MD
Tufts University School of Medicine and the New England Medical Center, Boston

Matthew R. Weir, MD
University of Maryland School of Medicine, Baltimore

Correspondence: Marvin A. Konstam, MD, New England Medical Center, 750 Washington Street, Box 108, Boston, MA 02111; e-mail: mkonstam@lifespan.org

Dr. Konstam has indicated that he has been a consultant for Merck, Pfizer, and Pharmacia and is on the speakers’ bureaus of Merck and Pfizer.

Dr. Weir has indicated that he has received grant or research support from Pharmacia, has been a consultant for Merck and Pharmacia, and is on the speaker’s bureau of Merck.